NVO vs. REGN
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or REGN.
Key characteristics
| NVO | REGN | |
|---|---|---|
| YTD Return | 35.72% | 34.89% |
| 1Y Return | 51.28% | 43.34% |
| 3Y Return (Ann) | 41.22% | 20.78% |
| 5Y Return (Ann) | 40.13% | 32.56% |
| 10Y Return (Ann) | 20.02% | 12.69% |
| Sharpe Ratio | 1.62 | 2.43 |
| Daily Std Dev | 30.37% | 17.26% |
| Max Drawdown | -51.96% | -91.81% |
| Current Drawdown | -4.92% | -1.42% |
Fundamentals
| NVO | REGN | |
|---|---|---|
| Market Cap | $612.29B | $129.88B |
| EPS | $2.99 | $37.93 |
| PE Ratio | 46.54 | 31.23 |
| PEG Ratio | 2.50 | 1.76 |
| Total Revenue (TTM) | $258.00B | $13.49B |
| Gross Profit (TTM) | $218.09B | $11.61B |
| EBITDA (TTM) | $130.97B | $4.46B |
Correlation
The correlation between NVO and REGN is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. REGN - Performance Comparison
The year-to-date returns for both stocks are quite close, with NVO having a 35.72% return and REGN slightly lower at 34.89%. Over the past 10 years, NVO has outperformed REGN with an annualized return of 20.02%, while REGN has yielded a comparatively lower 12.69% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. REGN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. REGN - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 0.85%, while REGN has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 0.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.17% |
REGN Regeneron Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
NVO vs. REGN - Drawdown Comparison
The maximum NVO drawdown since its inception was -51.96%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for NVO and REGN. For additional features, visit the drawdowns tool.
Volatility
NVO vs. REGN - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 14.65% compared to Regeneron Pharmaceuticals, Inc. (REGN) at 6.50%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities